Skip to main content
JW PHARMACEUTICAL logo

JW PHARMACEUTICAL — Investor Relations & Filings

Ticker · 001060 ISIN · KR7001060003 KO Manufacturing
Filings indexed 310 across all filing types
Latest filing 2024-02-06 Legal Proceedings Report
Country KR South Korea
Listing KO 001060

JW Pharmaceutical is a company focused on the research, development, and commercialization of pharmaceutical products. It provides a broad portfolio of therapeutic drugs, including specialty medicines and over-the-counter (OTC) solutions. Key product areas include nutritional infusions (Combiflex®, Winuf®), treatments for neutropenia (Neutrogin®), and cardiovascular medicines (Livalo®). Its consumer healthcare offerings feature the Hi-mom® brand of advanced wound care products. The company emphasizes innovation, advancing a pipeline of new drugs targeting oncology and immune diseases. This research is driven by proprietary technology platforms and includes candidates such as the gout treatment Epaminurad.

Recent filings

Filing Released Lang Actions
[기재정정]벌금등의부과
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from JW Pharmaceutical regarding the imposition of a fine (penalty) by the Korea Fair Trade Commission. It details the amount of the fine, the reason for the penalty (unfair customer inducement), and the company's future legal response. Since this document pertains to a regulatory action and legal penalty, it falls under the 'Legal Proceedings Report' category.
2024-02-06 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from JW Pharmaceutical regarding a change in sales or profit structure (30% or more). It provides preliminary financial results (revenue, operating profit, net income) for the fiscal year compared to the previous year. This type of disclosure is a standard regulatory requirement in the Korean market (DART system) for reporting significant financial changes before the final audit report is published. It fits the definition of an Earnings Release (ER) as it provides key financial highlights and performance drivers. FY 2023
2024-02-05 Korean
[기재정정]벌금등의부과
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from JW Pharmaceutical regarding the imposition of a fine (penalty) by the Korea Fair Trade Commission. It details the nature of the fine, the amount, the payment schedule, and the company's planned legal response. Since this relates to a regulatory action and legal/administrative penalty, it falls under the 'Legal Proceedings Report' category.
2024-01-18 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from JW Pharmaceutical regarding the adjustment of conversion prices for convertible preferred shares due to a bonus issue (free capital increase). This type of disclosure, which details changes to the capital structure and conversion terms of financial instruments, falls under the 'Share Issue/Capital Change' category as it directly impacts the company's equity and potential share dilution.
2023-12-29 Korean
수시공시의무관련사항(공정공시)
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from JW Pharmaceutical regarding the 2023 fiscal year cash dividend plan. It specifies the dividend amount per share type and the dividend record date. This falls directly under the definition of a dividend announcement.
2023-12-15 Korean
주요사항보고서(무상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean Financial Supervisory Service/Exchange, specifically detailing a 'Decision on Bonus Issue' (무상증자결정). This involves a change in the company's capital structure through the issuance of new shares to existing shareholders. According to the provided filing definitions, announcements regarding new share issues or capital changes fall under the 'Share Issue/Capital Change' (SHA) category.
2023-12-15 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.